GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by State Street Corp

State Street Corp boosted its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 153.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 277,234 shares of the company’s stock after purchasing an additional 167,742 shares during the period. State Street Corp owned about 0.07% of GoodRx worth $9,983,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Nuveen Asset Management LLC lifted its position in GoodRx by 63.1% in the second quarter. Nuveen Asset Management LLC now owns 1,647,703 shares of the company’s stock valued at $59,333,000 after purchasing an additional 637,566 shares during the period. CIBC Private Wealth Group LLC increased its holdings in GoodRx by 63.0% in the second quarter. CIBC Private Wealth Group LLC now owns 348,996 shares of the company’s stock valued at $12,569,000 after buying an additional 134,924 shares in the last quarter. Claro Advisors LLC purchased a new position in GoodRx in the second quarter valued at about $255,000. Marshall Wace LLP increased its holdings in GoodRx by 185.3% in the second quarter. Marshall Wace LLP now owns 74,626 shares of the company’s stock valued at $2,687,000 after buying an additional 48,469 shares in the last quarter. Finally, MML Investors Services LLC increased its holdings in GoodRx by 19.8% in the second quarter. MML Investors Services LLC now owns 16,801 shares of the company’s stock valued at $605,000 after buying an additional 2,777 shares in the last quarter. Hedge funds and other institutional investors own 51.29% of the company’s stock.

A number of brokerages have issued reports on GDRX. Deutsche Bank Aktiengesellschaft dropped their target price on shares of GoodRx from $47.00 to $44.00 and set a “hold” rating for the company in a report on Monday, November 15th. Zacks Investment Research cut shares of GoodRx from a “hold” rating to a “sell” rating in a research note on Thursday, November 18th. Barclays raised their price objective on shares of GoodRx from $45.00 to $47.00 and gave the stock an “overweight” rating in a research note on Thursday, November 11th. Raymond James raised shares of GoodRx from a “market perform” rating to an “outperform” rating and set a $45.00 price objective for the company in a research note on Friday, August 13th. Finally, Cowen dropped their price objective on shares of GoodRx from $44.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday, August 24th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $47.58.

In other GoodRx news, CFO Karsten Voermann sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 28th. The stock was sold at an average price of $40.31, for a total transaction of $302,325.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Babak Azad sold 12,500 shares of the stock in a transaction that occurred on Tuesday, November 9th. The stock was sold at an average price of $42.23, for a total value of $527,875.00. The disclosure for this sale can be found here. In the last quarter, insiders bought 817,927 shares of company stock valued at $31,217,412 and sold 1,135,886 shares valued at $48,935,998. 1.43% of the stock is currently owned by company insiders.

Shares of GDRX opened at $37.69 on Thursday. The firm has a market cap of $15.03 billion, a PE ratio of -53.08, a price-to-earnings-growth ratio of 43.49 and a beta of -0.88. The company’s fifty day moving average is $42.81 and its two-hundred day moving average is $37.76. GoodRx Holdings, Inc. has a fifty-two week low of $26.66 and a fifty-two week high of $59.67. The company has a quick ratio of 14.47, a current ratio of 14.47 and a debt-to-equity ratio of 0.78.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Wednesday, November 10th. The company reported $0.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.08. GoodRx had a negative net margin of 41.36% and a negative return on equity of 31.61%. During the same period last year, the firm posted ($0.25) EPS. As a group, equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.03 earnings per share for the current year.

GoodRx Profile

GoodRx Holdings, Inc, through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Further Reading: What are economic reports?

Want to see what other hedge funds are holding GDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX).

Institutional Ownership by Quarter for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.